Immune-based strategies to achieve HIV remission are increasingly focusing on ways to boost the body’s ability to control persistent viral reservoirs. Among these approaches, natural killer (NK) cells could be genetically engineered to enhance their ability to recognize and eliminate HIV-infected cells and overcome viral evasion mechanisms. Researchers discussed this emerging strategy at the 26th International AIDS Conference (AIDS 2026), which is taking place July 26-31, 2026, in Rio de Janeiro, Brazil. Read More
Researchers from Thor Therapeutics Inc. and collaborators reported the efficacy of A-427, a CNS-targeted antisense oligonucleotide (ASO) that selectively suppresses Gfral expression, in preclinical models of cancer-associated cachexia. The brainstem-restricted receptor GFRAL, which mediates the cachexia-inducing effects of tumor-derived GDF15, has emerged as a translational target for therapies designed to counteract tumor-associated wasting and weight loss. Read More
Sail Biomedicines Inc. has established a strategic collaboration with Johnson & Johnson (J&J) to advance innovative in vivo CAR T therapies for immune-mediated diseases. Read More
Abcellera Biologics Inc. has established a collaboration with Vertex Pharmaceuticals Inc. to research, develop, manufacture and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Read More
Iksuda Therapeutics Ltd. has obtained IND clearance from the FDA for IKS-04, enabling initiation of a phase I trial in patients with gastrointestinal cancers. Read More
Shanghai Qilu Pharmaceutical Research Development Centre Ltd. has identified soluble guanylate cyclase (sGC) activators that are potentially useful for the treatment of chronic kidney disease and diabetic nephropathy. Read More
CAR T-cell therapy has been highly effective in hematologic cancers but faces challenges in solid tumors due to the lack of safe, uniformly expressed surface antigens. A recent study found that the MiT/TFE-family fusion-driven glycoprotein NMB (GPNMB) is highly, homogeneously and stably expressed in primary and relapsed alveolar soft-part sarcoma (ASPS) and translocation renal cell carcinoma (tRCC). Read More
Insilico Medicine Inc. has patented cyclin-dependent kinase (CDK) inhibitors, particularly CDK2/cyclin E1 and/or and CDK4/cyclin D3, reported to be useful for the treatment of cancer. Read More
Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd. has reported GTPase KRAS (G12D mutant) inhibitors found to be useful for the treatment of non-small-cell lung and pancreatic cancer. Read More
Beta Pharma Inc. has disclosed antibody-drug conjugates consisting of humanized monoclonal antibody trastuzumab targeting receptor tyrosine-protein kinase erbB-2 (erbB2; HER2) covalently linked to cytotoxic drug through a cleavable linker reported to be useful for the treatment of cancer. Read More
Shanghai Zheye Biotechnology LLC has prepared and tested new phenylpropionic acid derivatives acting as apolipoprotein A (ApoA; LPA)/apolipoprotein B-100 (APOB) interaction inhibitors that are potentially useful for the treatment of stroke, atherosclerosis, thrombosis, coronary heart disease and aortic valve stenosis. Read More
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and disease. Read More
